期刊文献+

骨肉瘤MG-63细胞中Survivin的表达及其反义寡核苷酸对细胞增殖与凋亡的作用 被引量:7

The expression of survivin in osteosarcoma MG-63 cells and the effect of survivin antisense oligonucleotide on its proliferation and apoptosis
下载PDF
导出
摘要 目的探讨Survivin在骨肉瘤细胞中的表达及Survivin反义寡核苷酸(ASODN)对骨肉瘤MG-63细胞增殖和凋亡的影响。方法设计针对Survivin的ASODN和正义核苷酸(SODN)序列,制备脂质体-寡核苷酸复合物并转染MG-63细胞,分为空脂质体(Lip)组、脂质体介导的SODN(Lip-SODN)组和脂质体介导的ASODN(Lip-ASODN)组。采用免疫细胞染色法检测MG-63细胞中Survivin的表达情况,Western blotting检测各组转染48h后的Survivin蛋白水平,MTT法检测转染24、48和72h后MG-63细胞的增殖情况,流式细胞仪检测转染48h后MG-63细胞的凋亡情况。结果 Survivin主要表达于MG-63细胞的胞核。Lip-ASODN组的Survivin蛋白水平均低于Lip-SODN组和Lip组。不同浓度Survivin ASODN对MG-63细胞的增殖抑制程度不同,Lip-ASODN组的细胞增殖抑制率高于Lip组,且呈浓度依赖性;而Lip-SODN组的增殖抑制率与Lip组的差异无统计学意义(P>0.05)。Lip-ASODN组的凋亡率为(88.47±0.79)%,高于Lip组的(10.01±0.90)%和Lip-SODN组的(4.12±0.25)%,差异有统计学意义(P<0.05)。结论靶向Survivin的ASODN可以显著抑制骨肉瘤MG-63细胞的增殖能力,并促进其凋亡。 Objective To investigate the expression of survivin in osteosarcoma MG-63 cells and the effect of survivin anti- sense oligonucleotide(ASODN) on its proliferation and apoptosis. Methods The ASODN and sense oligonucleotide(SODN) targeting survivin were designed and constructed. The liposome/oligonucleotide complexes were prepared by adding oligonucleotide and then transferred into MG-63 cells. According to the protocol, the MG-63 cells were assigned into Lip group (empty liposome) , Lip-SODN group (liposome-mediated SODN) and Lip-ASODN group (liposome-mediated ASODN). The immunohistochemieal staining was used to detect the expression of survivin in MG-63 cells. Western blotting assay was employed to measure the protein levels of survivin at 48th hour after transfection of each group. The proliferation at 24th, 48th and 72nd hour and apoptosis at 48th hour after transfection were measured by MTT and flow cytometry, respectively. Results The survivin was mainly expressed in the nucleus of MG-63 cells. The protein level of Lip-ASODN group was lower than that of Lip group and Lip-SODN group. The Lip-ASODN group's proliferation inhibi- tion rate was superior to Lip group in a dose-dependent manner, while the difference between Lip-SODN group and Lip group was not significant(P〉0. 05). The apoptotie rate of Lip-ASODN group was( 88.47±0. 79) %, higher than( 10.01±0. 90) % of Lip group and (4. 12±0. 25) % of Lip-SODN group with significant difference(P〈0. 05). Conclusion The ASODN targeting survivin can inhibit the proliferative capacity and promote the apoptosis of osteosarcoma MG-63 cells.
出处 《临床肿瘤学杂志》 CAS 2014年第1期14-17,共4页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(81102039)
关键词 反义寡核苷酸 SURVIVIN蛋白 骨肉瘤 细胞增殖 凋亡 Antisense oligonucleotides Survivin protein Osteosarcoma Cell proliferation Apoptosis
  • 相关文献

参考文献10

  • 1Smith BR,Stabile BE. Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young[J].{H}Archives of Surgery,2009,(2):506-510.
  • 2Nedelcu T,Kubista B,Koller A. Livin and Bcl-2 expression in high-grade osteosarcoma[J].{H}Cancer Research and Clinical Oncology,2008,(2):237-244.
  • 3刘卓星,刘文玲.Survivin、Ki-67在口腔颌面部非霍奇金淋巴瘤中的表达及竟义[J].临床肿瘤学杂志,2013,18(8):695-698. 被引量:5
  • 4林任,廖前德,吕红斌.Survivin蛋白在人骨肉瘤、骨软骨瘤和正常骨组织中表达的初步研究[J].中国现代医学杂志,2010,20(21):3263-3266. 被引量:4
  • 5Roshdy N,Mostafa T. Seminal plasma survivin in fertile and infertile males[J].{H}Journal Of Urology,2009,(3):1269-1272.
  • 6Zhang HZ,Wang Y,Gao P. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumorcells[J].{H}CANCER BIOLOGY & THERAPY,2006,(11):1457-1461.
  • 7Osaka E,Suzuki T,Osaka S. Survivin expression levels as independent predictors of survival for osteosarcoma patients[J].{H}Journal of Orthopaedic Research,2007,(1):116-121.
  • 8Wu YF,Hang X.J,Liu YY. Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63[J].Neoplasm,2010,(6):501-506.
  • 9Liang X,Da M,Zhuang Z. Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro[J].{H}Cell Biology International,2009,(1):119-124.
  • 10饶耀剑,刘慧娟,夏仁云.survivin反义寡核苷酸抑制骨肉瘤细胞增殖及增加化疗敏感性的作用[J].医学研究生学报,2006,19(2):132-135. 被引量:9

二级参考文献29

  • 1孔宪寿,金志军.反义核酸对肿瘤的治疗作用[J].中国肿瘤生物治疗杂志,1995,2(1):61-65. 被引量:4
  • 2向晓娟,何友兼,李宇红,黄河,徐菲.周围T细胞淋巴瘤survivin表达的临床意义[J].癌症,2006,25(6):758-761. 被引量:6
  • 3MESRI M, WALL NR, LI J, et al. Cancer gent therapy using a survivin mutant adenovirus [J]. J Clin Invest, 2001, 108 (7): 981-990.
  • 4SMITH SD, WHEELER MA, PLESCIA J, et aLUrine detection of survivin and diagnosis of bladder cancer[J]. JAMA, 2001, 285(3): 324-328.
  • 5HAI LONG YANG, YANG BING DONG, Mary Jane Eliott, et al. Additive effective of adenovirus-mediated E2F-lgene transfer and topoisomerase 2 inhibitors on apoptosis in human osteosar- coma cell[J]. Cancer Gene Therapy, 2001, 8(4): 241-251.
  • 6BRESALIER RS, HO SB, SCHOEPPrqER HL, et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis [J]. Gastroenterology, 1996, 110 (5): 1354-1367.
  • 7ABROSINI G, ALTIERI D C, et al. Induction of apoptosis and inhibition of con proliferation by survivin gene targeting[J]. J Biol Chem, 1998, (273): 11177-11182.
  • 8IKEGUCHI M, KAIBARA N. Changes in survivin messenger RNA level during cisplatin treatment in gastrie cancer [J]. Int J Mol Med, 2001, 8(6): 661-666.
  • 9SELA B. Survivin: anti-apoptosis protein and a prognostic marker for tumor progression and recurrence [J]. Harefuah, 2002, 141(1): 103-107, 123.
  • 10ZAFFARONI N, DAIDONE MG. Survivia expression and resistance to anticaneer treatments: perspectives for new therapeutic interventions[J]. Drug Resist Updat, 2002, 5(2): 65-72.

共引文献14

同被引文献57

  • 1李恩惠,辛杰,张忠礼,张圣军,李湘州.Survivin与Fas在骨肉瘤中的表达、临床意义及相关性[J].中国矫形外科杂志,2013,21(23):2383-2388. 被引量:2
  • 2Li JZ, Tian ZQ, Jiang SN, et al. Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy [ J ]. Genet Mol Res, 2014, 13(2) :3186-3192.
  • 3Nieves BJ, D'Amore PA, Bryan BA. The function of vascular en-dothelial growth factor [ J ]. Biofactors, 2009, 35 (4) : 332- 337.
  • 4Vaziri SA, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor poIymorphisms : role in response and toxicity of tyro- sine kinase inhibitors [ J]. Curr Oncol Rep, 2010, 12 (2) : 102 - 108.
  • 5Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer[ J] .Int J Radiat Oncol Biol Phys, 2010, 76(3) :824-830.
  • 6Chowdury MW, Scaramuzzi RJ, Wheeler-Jones CP, et al. The expression of angiogenic growth factors and their receptors in o- varian follicles throughout the estrous cycle in the ewe [ J l.Ther- iogenology, 2010, 73(7) :856-872.
  • 7Becouam Y, Cany L, Pulido M, et al. FOLFIRI(R) and Bev- acizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms [ J ]. BMC Res Notes, 2014, 7(1) :260.
  • 8Gao YS, Mei J, Tong TL, et al. Inhibitory effects of VEGF- siRNA mediated by adenovirus on osteosarcoma-bearing nude mice [ J ]. Cancer Biother Radiopharm, 2009, 24 (2) : 243- 247.
  • 9Turner DC, Navid F, Daw NC, et al. Population phannacokinetics of bevacizumab in children with osteosarcorna: implications for do- sing[J]. Clin Cancer Res, 2014, 20(10) :2783-2792.
  • 10Chowdury MW, Scaramuzzi R J, Wheeler-Jones CP, et al. The expression of angiogenic growth factors and their receptors in o- varian follicles throughout the estrous cycle in the ewe [ J ]. Ther- iogenology, 2010, 73(7):856-872.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部